Education
About Us
Working with TipRanks
Follow Us
Takeda Pharmaceutical Co Ltd (TKPHF)
OTHER OTC:TKPHF
RESEARCH TOOLSreports
Total Valuation
Takeda Pharmaceutical Co has a market cap or net worth of $43.70B. The enterprise value is $11.17T.
Market Cap$43.70B
Enterprise Value$11.17T
Share Statistics
Takeda Pharmaceutical Co has 1.59B shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1.59B
Owned by Insiders
Owned by Instutions<0.01%
Financial Efficiency
Takeda Pharmaceutical Co’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee$92,916,560.135
Profits Per Employee$4,222,945.963
Employee Count49,281
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Takeda Pharmaceutical Co is ―. Takeda Pharmaceutical Co’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Takeda Pharmaceutical Co had revenue of $4.58T and earned $208.11B in profits. Earnings per share was $131.96.
Revenue$4.58T
Gross Profit$2.51T
Operating Income$471.44B
Pretax Income$231.83B
Net Income$208.11B
EBITDA1.20T
Earnings Per Share (EPS)131.96
Cash Flow
In the last 12 months, operating cash flow was $1.07T and capital expenditures -$308.25B, giving a free cash flow of $766.36B billion.
Operating Cash Flow$1.07T
Free Cash Flow$766.36B
Free Cash Flow per Share$481.70
Dividends & Yields
Takeda Pharmaceutical Co pays an annual dividend of $0.67, resulting in a dividend yield of 4.97%
Dividend Per Share$0.67
Dividend Yield4.97%
Payout Ratio74.10%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.08
52-Week Price Change12.30%
50-Day Moving Average28.36
200-Day Moving Average27.03
Relative Strength Index (RSI)32.05
Average Volume (3m)16.13K
Important Dates
Takeda Pharmaceutical Co upcoming earnings date is May 8, 2025, Before Open.
Last Earnings DateJan 30, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend DateMar 28, 2025
Financial Position
Takeda Pharmaceutical Co as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Takeda Pharmaceutical Co has paid $26.61B in taxes.
Income Tax$26.61B
Effective Tax Rate―
Enterprise Valuation
Takeda Pharmaceutical Co EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Takeda Pharmaceutical Co has $526.75B in cash and marketable securities with $4.84T in debt, giving a net cash position of $4.31T billion.
Cash & Marketable Securities$526.75B
Total Debt$4.84T
Net Cash$4.31T
Net Cash Per Share$2.71K
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Takeda Pharmaceutical Co is $35.82, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$35.82
Price Target Upside25.77%
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast
EPS Growth Forecast